Combining with a PI3K/mTOR pathway inhibitor mitigated the CHK1 inhibitor-induced RAD51-mediated HR repair and augmented replication stress, leading to cell death in high-grade serous ovarian carcinoma (44). This evidence concerns the gene MTOR and ovarian serous carcinoma.